 DUBLIN SAN DIEGO--BUSINESS WIRE--Horizon Therapeutics plc Nasdaq: HZNP and Halozyme Therapeutics, Inc. Nasdaq: HALO today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozymes ENHANZE drug delivery technology for subcutaneous SC formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE to develop a SC formulation of TEPEZZA teprotumumab-trbw, indicated for the treatment of Thyroid Eye Disease, a serious, progressiv 